Form 4: Clover Health CEO Jamie Reynoso Reports Stock Transactions Following RSU Vesting

Sentiment:

SEC Form 4


Jamie Reynoso, CEO of Medicare Advantage at Clover Health, reports acquisition of shares through RSU vesting and subsequent withholding for tax obligations.

Summary

  • Jamie Reynoso, CEO of Medicare Advantage at Clover Health, filed a Form 4 detailing changes in beneficial ownership.
  • On September 13, 2024, Reynoso acquired 259,000 shares of Class A Common Stock through the vesting of restricted stock units (RSUs) related to performance achievement.
  • Also on September 13, 2024, 101,917 shares were withheld to cover tax obligations at a price of $2.99 per share.
  • Additional shares were withheld on September 14 and 15, 2024, to cover tax obligations related to the vesting of RSUs granted in March and September 2022, respectively, also at $2.99 per share.
  • Following these transactions, Reynoso directly owns 2,754,445 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock transactions by a company insider. The vesting of RSUs suggests performance targets were met, which is mildly positive. However, the tax withholding is a neutral event.

Positives

  • The vesting of RSUs indicates that performance targets were met, which could be seen as a positive signal.

Future Outlook

The remaining one-half of the performance-based restricted stock units will vest on October 31, 2025, subject to continued employment. Remaining RSUs from grants in March and September 2022 will continue to vest in equal quarterly installments until March 14, 2026, and September 16, 2026, respectively, subject to continued service.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. The vesting of RSUs and subsequent tax withholding are common occurrences.

Comparison to Industry Standards

  • Stock-based compensation is a common practice among publicly traded companies, particularly in the technology and healthcare sectors, to align management's interests with those of shareholders.
  • Companies like UnitedHealth Group (UNH) and Humana (HUM) also utilize stock-based compensation as part of their executive compensation packages.
  • The vesting schedules and terms of these grants are typically detailed in the company's proxy statements.

Stakeholder Impact

  • Shareholders may view the vesting of RSUs as a sign that performance targets are being met.
  • Employees who hold RSUs are directly impacted by the vesting schedules and tax implications.

Key Dates

DateDescription
03/14/2022Date of original RSU grant to the Reporting Person.
03/16/2022Form 4 filed for RSU grant on March 14, 2022.
09/16/2022Date of original RSU grant to the Reporting Person.
09/20/2022Form 4 filed for RSU grant on September 16, 2022.
10/31/2023Date of performance-based restricted share unit grant.
09/13/2024Vesting and settlement of one-half of earned performance-based restricted stock units; tax withholding.
09/14/2024Vesting of 6.25% of RSUs granted on March 14, 2022; tax withholding.
09/15/2024Vesting of 6.25% of RSUs granted on September 16, 2022; tax withholding.
09/17/2024Date of Form 4 filing.
10/31/2025Remaining one-half of the restricted stock units will vest.
03/14/2026Final vesting of RSUs granted on March 14, 2022.
09/16/2026Final vesting of RSUs granted on September 16, 2022.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.